Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-18

Clinical Trial Update: A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial updating the study of bran-brutinib (BMS-986166) for atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Br Branebrutinib (BMS-986166) (branebrutinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Dermatitis, Atopic | Phase 2 | Status: COMPLETED | Results posted: 2023-10-18